What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy

Regeneron buys 23andMe Getty ImagesRegeneron Pharmaceuticals announced on Monday it will acquire bankrupt genomics firm 23andMe for $256 million through a bankruptcy auction, promising to maintain ethical standards in handling sensitive customer DNA information.According to Reuters, the New York-based pharmaceutical giant aims to leverage 23andMe’s extensive database of over 15 million customer DNA samples to enhance its genomic-driven drug discovery processes. The acquisition comes at a crucial time as con ...